Prostate Cancer Treatment and Research

Moving in Cancer Discovery and The Lancet.

Moved, week to 23 Oct 2026: 2
Papers in 60 days: 18

Add Prostate Cancer Treatment and Research as an interest in JClubFree on iPhone and Android · interests shape Home, Discover and your digest

Rebuilt 23 October 2026 at 12:56 pm AEDT

Moved this week

Everything that moved →

[(177)Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.
The Lancet · 29 Aug 2026 · Randomized Controlled Trial
Read the AI summary in JClub
- 1 cited this week
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42561994
Open in JClub
PROTEUS May Mean New SOC for Some Prostate Cancers.
Cancer Discovery · 9 June 2026 · News
Six months of apalutamide combined with ADT increases 5-year metastasis-free survival to 78.2% in high-risk localized prostate cancer patients.
- In the news
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42261650
Open in JClub

Latest in Prostate Cancer Treatment and Research

Newest first · last 60 days

Thermodynamic Quality Control Reshapes Spatially Resolved Metabolic Flux Predictions in Prostate Cancer
bioRxiv · 21 Oct 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.06.25.734531
Open in JClub
The molecular heterogeneity and clinical impact of genomic driver alterations in prostate cancer.
Nature Communications · 16 Oct 2026 · Journal Article
Recurrent genomic driver alterations are identified in 97% of primary prostate tumors, revealing four distinct oncotypes with varying clinical outcomes.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42888190
Open in JClub
A Mechanistic Model of Caspase-mediated Apoptosis Signaling Reveals Regulators of Drug Resistance in Prostate Cancer Cells
bioRxiv · 16 Oct 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.03.09.710645
Open in JClub
Reframing cancer therapy through tumor plasticity.
Nature Cancer · 14 Oct 2026 · Review
Reversible cellular plasticity enables tumor cells to bypass targeted therapies, contributing to drug tolerance and resistance in cancer treatment.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42875653
Open in JClub
Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial.
Nature Medicine · 14 Oct 2026 · Journal Article
Talazoparib plus enzalutamide achieved a 73% PSA <0.2 ng/ml response rate at 12 months in high-volume metastatic hormone-naive prostate cancer, exceeding efficacy thresholds.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42875559
Open in JClub
Cytoplasmic FKBP7 reflux sustains NFE2L1 levels in an adaptive response to chemotherapy in prostate cancer cells
bioRxiv · 14 Oct 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.01.18.700172
Open in JClub
Proteome-guided drug discovery maps and mitigates therapeutic degrader toxicity.
Nature Chemical Biology · 9 Oct 2026 · Journal Article
Proteome-guided drug discovery identified linker modifications that reduce hepatotoxicity and improve safety of androgen receptor-targeting degraders for prostate cancer.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42855516
Open in JClub
Molecular stratification of SPOP-mutant prostate cancer demonstrates Wnt signaling and replication stress signatures in diverse patient populations.
Cell Reports · 6 Oct 2026 · Journal Article
SPOP-mutant prostate cancer exhibits Wnt pathway dysregulation and diverse transcriptional signatures across racial groups, with 40 tumors analyzed for genomic and transcriptomic features.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42842364
Open in JClub
From inherited susceptibility to tumor state: toward a stage-aware architecture for genomic risk stratification in prostate cancer.
Frontiers in Genetics · 1 Oct 2026 · Review
Biologically informed machine learning enables stage-aware genomic risk stratification in prostate cancer, integrating inherited susceptibility and tumor biology.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42889514
Open in JClub
Disruption of NUAK2-Mediated RNA Splicing by Trilaciclib Reveals a Therapeutic Vulnerability in AR-Indifferent Prostate Cancer
bioRxiv · 25 Sept 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.1101/2025.11.12.687734
Open in JClub
Loss of NCOA6 protein causes aggressive prostate cancer with EGFR overexpression and dependency.
Nature Communications · 15 Sept 2026 · Journal Article
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42875450
Open in JClub
Identification and Characterization of PCAHIT, a Novel Long Non-Coding RNA Associated with Poor Outcomes in Prostate Cancer
bioRxiv · 10 Sept 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.1101/2025.05.21.655369
Open in JClub
Mass Spectrometry-Based Profiling of Deuterium-Labeled Sex Steroids Enables Non-Invasive Mapping of Steroid Dynamics in Intact Mice
bioRxiv · 9 Sept 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2025.12.16.694587
Open in JClub
Integrated signatures define mutational processes in prostate cancer.
Nature · 9 Sept 2026 · Journal Article
Integrated mutational signatures in prostate cancer reveal eight key footprints explaining 85% of genomes and link to clinical outcomes.
- Open access
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42717097
Open in JClub
Recurrent mechanisms of biallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer.
Nature Communications · 9 Sept 2026 · Journal Article
Biallelic epigenetic inactivation of ZFHX3 occurs at a recurrence rate comparable to TP53 in prostate cancer, promoting oncogene upregulation and metastasis.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42716948
Open in JClub
The benefits, harms, and cost-effectiveness of age-based and risk-stratified screening for prostate cancer with MRI
medRxiv · 9 Sept 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2025.11.28.25341221
Open in JClub
DNA damage repair gene defects combined predict the efficacy of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: a retrospective cohort study.
Frontiers in Genetics · 1 Sept 2026 · Journal Article
Combined DDR gene mutation profiling with TMB and PD-L1 predicts immunotherapy response in 152 metastatic castration-resistant prostate cancer patients, with an AUC of 0.83.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42741774
Open in JClub
Hepatic steatosis as an architect of CRC metastatic niche.
Journal of hepatology · 25 Aug 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42642312
Open in JClub

Add Prostate Cancer Treatment and Research as an interest in JClub

Journals this month

All journals →

Topics moving, week to 23 Oct 2026

All topics →

By field

All journals by field →

Moved this week

Latest in Prostate Cancer Treatment and Research

Browse JClub